BNB Plus' Subsidiary Granted Patent By European Patent Office For Application 21882234.4 Entitled Compositions and Methods for RNA Synthesis

BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis."

The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP. The Company plans to validate the patent in key European markets to provide patent protection through at least 2040.